news
South African Regulators Win Court Battle Over Bootleg GLP-1 Injections
South African health authorities won a landmark court ruling against a local pharmacy compounding unauthorized weight-loss injections. Black-market sellers continue hawking unregulated semaglutide and experimental peptides across social platforms while stricter rules remain months away. The enforcement battle highlights the global struggle to police off-label metabolic drugs when genuine pens remain unaffordable.
South African health authorities won a landmark court ruling against a local pharmacy compounding unauthorized weight-loss injections. Black-market sellers continue hawking unregulated semaglutide and experimental peptides across social platforms while stricter rules remain months away. The enforcement battle highlights the global struggle to police off-label metabolic drugs when genuine pens remain unaffordable.
The architecture take
I used to think black-market GLP-1 compounding was mostly an American problem tied to FDA shortage loopholes. South Africa's high court victory against compounding pharmacies proves the hunger for off-label semaglutide is completely global. People want cheap access to peptides that silence food noise, slow gastric emptying, and steady blood sugar. When genuine pens cost half a month's rent, buyers turn to unverified vials sold over messaging apps. (Predictably, testing these batches usually turns up incorrect dosing or raw peptide salts meant for research labs.) I spent months talking to clinicians who treat the fallout: severe nausea, pancreatitis, and patients who accidentally inject ten times their intended dose. Now I see regulators chasing an impossible tail. The nervous system pays an ugly penalty when unregulated peptides shock the gut-brain axis. Boring biology gets messy fast. Underground supply chains move faster than civil courts, and demand won't drop until licensed pens become affordable.